Evidence-Based Pharmacotherapies for Panic Disorder

Abstract

This chapter presents a review of the primary psychopharmacological interventions for panic disorder and the empirically derived evidence supporting their continued use. Key factors such as dosing, contraindications, safety, tolerability, and polypharmacy are discussed. The chapter will include a currently supported tier structure for pharmacological treatment planning as well as means for how best to tailor regimens to specific patient needs. Comorbidities and practical applications are addressed as well. Lastly, the chapter closes with some emerging pharmacotherapies that show promise but for which empirical evidence supporting their use remains in its infancy.

Biological and cognitive theories explaining panic disorder: A narrative review

“…In summary, the biological theories have provided well-grounded comprehension into discerning the pathophysiology and etiology of PD. Whilst biological theories have informed psychopharmacological treatments that have been successful in treating panic attacks ( 114 , 115 ), there are a number of emerging trends from the biological area. The empirical and clinical evidence suggests that first-line psychopharmacological treatments for PD include SSRI's and benzodiazepines.…”

Enhancing panic disorder treatment with mobile-aided case management: an exploratory study based on a 3-year cohort analysis

“…The treatment-as-usual (TAU) approach for panic disorder typically consists of pharmacotherapy ( 11 , 12 ) and psychological and/or behavioral interventions, such as cognitive-behavioral therapy (CBT) ( 13 – 15 ) or relaxation. Extensive evidence supports the effectiveness of these TAU approaches in reducing the frequency and intensity of panic attacks and improving the overall quality of life ( 16 ).…”